
17 April 2023



First shipment to llios Santé in Germany

Highlights:

- First shipment of new high THC strain delivered to Ilios Santé in Germany
- Opens pathway to second major German medicinal cannabis distributor in addition to Demecan
- Follows further Danish shipment to Demecan with deliveries reinforcing LGP's first-mover European strategy
- llios Santé is a wholly-owned subsidiary of The Bloomwell Group, a leading European medical cannabis healthcare group



Based on the minimum annual quantities to be purchased by Ilios Santé during the two-year term, the Agreement has a value of ~\$2.3 million (~€1.4 million²), with ~80% of the minimum quantities falling in the second year. Further details in relation to the supply agreement is set out in the ASX announcement dated 12 July 2022.

¹See ASX announcement re supply agreement between LGP Denmark and Deutsche Medizinalcannabis GmbH dated 19 April 2022 ² EUR:AUD 0.6128 (as at 14 April 2023)





With signing of commercial terms back in July 2022, the shipment represents the culmination of a nine-month engagement process that includes obtaining licences, vendor qualification and quality assurance audit, and finalising quality arrangements between the parties.

The long lead-time between commercial terms and first shipment due to the extensive quality and regulatory requirements associated with shipping pharmaceuticals between countries, mean first-mover suppliers are frequently best placed in new markets given the time and effort distributors face qualifying and approving replacement supply arrangements with new vendors. LGP regards this insight as critical in understanding LGP's long-term strategy to grow and consolidate market gains in existing territories while continuing to move rapidly into new European markets.

About Ilios Sante and the Bloomwell Group

Ilios Santé is an EU Good Distribution Practices (GDP) licensed pharmaceutical wholesaler headquartered in Frankfurt, Germany. It is a wholly owned subsidiary of leading German medical cannabis healthcare company, The Bloomwell Group, a holding company for medical cannabis companies with a mission to build, acquire and invest in ESG healthcare companies along the entire value chain outside of cultivation.

As a member of the Bloomwell Group, Ilios Santé is part of a fully integrated group of distinct cannabis-related brands each fulfilling a distinct purpose, including Ilios Santé in the medicinal cannabis space, Algea Care, Europe's leading telemedicine platform, and Bloomwell's lifestyle brand, Breezy.

ENDS BY ORDER OF THE BOARD

Alistair Warren
Company Secretary





For further information please contact:

Alistair Warren Company Secretary

Little Green Pharma E: <u>a.warren@lgp.global</u> T: +618 6280 0050 Fleta Solomon
Chief Executive Officer
Little Green Pharma

E: f.solomon@lgp.global T: +618 6280 0050

About Little Green Pharma

 $Little \ Green \ Pharma \ is \ a \ global, vertically \ integrated \ and \ geographically \ diverse \ medicinal \ cannab \ is \ business \ with \ operations \ from \ cultivation \ and \ production \ through \ to \ manufacturing \ and \ distribution.$

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m² cultivation and 4,000m² GMP manufacturing facility capable of producing over 30 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp